Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamíð - flogaveiki, partial - antiepileptics, - lacosamide ucb er ætlað eitt og sér og venjulega meðferð í meðferð á hluta-upphaf flog með eða án efri almenn ákvörðun er tekin í fullorðnir, unglingum og börn, frá 4 ára aldri með flogaveiki.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamíð - flogaveiki - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamíð - flogaveiki - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - endaþarmsstíll - 1 g

Evrópusambandið - íslenska - EMA (European Medicines Agency)

theravia - cholic sýru - digestive system diseases; metabolism, inborn errors - galli sýra og afleiður - orphacol er ætlað fyrir meðferð meðfæddan villur í aðal galli-sýru myndun vegna 3β-hýdroxý-Δ5-c27-stera oxidoreductase skort eða Δ4-3-oxosteroid-5β-redúktasa skort á börn, börn og unglingar á aldrinum einn mánuð til 18 ára og fullorðnir.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ucb pharma sa - lacosamíð - flogaveiki - antiepileptics, - vimpat er ætlað sem einlyfjameðferð og viðbótarmeðferð við meðhöndlun á flogaveiki með eða án aukakvilla hjá fullorðnum, unglingum og börnum frá 4 ára með flogaveiki.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 400 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 800 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - lyf til veikindi öndunarvegi sjúkdómum, - budesonid / formoterol teva pharma b. er ætlað fullorðnum 18 ára og eldri. asthmabudesonide/formóteróli sjá pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.